N-acetylcysteine in the Prevention of Contrast-induced Acute Kidney Injury: a Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials
Open Access
- 8 September 2022
- journal article
- review article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 18 (4), 455-461
- https://doi.org/10.20996/1819-6446-2022-08-10
Abstract
Aim. To analyze the currently available published randomized controlled clinical trials to evaluate the effect of N-acetylcysteine on the incidence of contrast-induced acute kidney injury (CI-AKI). Material and methods. The meta-analysis was performed in accordance with the PRISMA guidelines based on a search of existing literature in the PubMed/MEDLINE database for the period from 2015 to 16 February 2022. Keywords included MeSH terms «acute kidney injury» or «contrast-induced nephropathy» or «AKI» or «CIN» and «contrast media» and «N-acetylcysteine». The RoB 2 tool was used to assess study bias. Results: When searching based on the initially selected statistics, 98 publications were identified, some of them were excluded from the analysis due to non-compliance with the inclusion criteria in this meta-analysis, 7 studies of unused sources of detection were ultimately selected, the total number of patients in the discovery was 10394.The results of the meta-analysis revealed that in patients treated with N-acetylcysteine CI-AKI developed with the same frequency as in patients who did not observe such therapy as a prophylaxis for this disease (odds ratio 1.06, 95% confidence interval 0.911.23, p=0.46). Conclusion. The use of N-acytelcysteine does not offer any advantage in reducing the incidence of CI-AKI compared with the administration of saline solutions (sodium bicarbonate or sodium chloride 0.9%) or placebo.Keywords
This publication has 17 references indexed in Scilit:
- Outcomes after Angiography with Sodium Bicarbonate and AcetylcysteineThe New England Journal of Medicine, 2018
- Contrast-associated acute kidney injury is a myth: YesIntensive Care Medicine, 2017
- The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled studyCritical Care, 2017
- Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome ManagementJournal of the American College of Cardiology, 2017
- Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysisPLOS ONE, 2017
- AKIGUARD (Acute Kidney Injury GUARding Device) trialJournal of Cardiovascular Medicine, 2016
- N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trialSaudi Journal of Kidney Diseases and Transplantation, 2016
- Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trialInternational Journal of Cardiology, 2015
- NoticeKidney International Supplements, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011